Burcon NutraScience (BU) EPS Estimated At $0.00, Vera Bradley (VRA) Sentiment Is 1.35

June 8, 2017 - By Marguerite Chambers

Analysts expect Burcon NutraScience Corp (TSE:BU) to report $0.00 EPS on June, 26. The stock decreased 2.07% or $0.03 on June 7, reaching $1.42. About 27,360 shares traded. Burcon NutraScience Corp (TSE:BU) has 0.00% since June 8, 2016 and is . It has underperformed by 16.70% the S&P500.

Vera Bradley, Inc. is a designer of women’s handbags, accessories, luggage and travel items, eyewear, and stationery and gifts. The company has market cap of $293.06 million. The Company’s divisions include Direct and Indirect. It has a 23.18 P/E ratio. The Firm offers various products, including bags, travel, home and accessories.

Burcon NutraScience Corp is a Canada company, which is engaged in development of functional and renewable plant proteins. The company has market cap of $59.91 million. The Firm has developed a portfolio of composition, application and process patents originating from a core protein extraction and purification technology. It currently has negative earnings. The Firm and its subsidiary have developed CLARISOY, a soy protein; and are developing Peazazz, a pea protein, and Puratein, Supertein and Nutratein, approximately three canola protein isolates.

Daruma Capital Management Llc holds 2.18% of its portfolio in Vera Bradley, Inc. for 3.27 million shares. Tieton Capital Management Llc owns 93,940 shares or 0.86% of their US portfolio. Moreover, Lucus Advisors Llc has 0.37% invested in the company for 13,510 shares. The Indiana-based Monarch Capital Management Inc has invested 0.35% in the stock. Trexquant Investment Lp, a Connecticut-based fund reported 63,721 shares.

The stock increased 0.24% or $0.02 during the last trading session, reaching $8.35. About shares traded. Vera Bradley, Inc. (VRA) has declined 49.97% since June 8, 2016 and is downtrending. It has underperformed by 66.67% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: